Tofacitinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4341 publications

Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital.

Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital.

Journal: Indian journal of dermatology

Published: September 08, 2026

Effect of JAK inhibitors on extraintestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease.

Effect of JAK inhibitors on extraintestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease.

Journal: Journal of Crohn's & colitis

Published: September 05, 2026

Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression.

Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression.

Journal: Journal of Crohn's & colitis

Published: August 08, 2026

Retraction notice to "Rapid cutaneous remission response to tofacitinib and systemic corticosteroids in VEXAS syndrome with a novel UBA1 mutation" [JAAD Case Reports 68 (2026) 105-107].

Retraction notice to "Rapid cutaneous remission response to tofacitinib and systemic corticosteroids in VEXAS syndrome with a novel UBA1 mutation" [JAAD Case Reports 68 (2026) 105-107].

Journal: JAAD case reports

Published: August 06, 2026

Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study.

Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study.

Journal: Journal of drugs in dermatology : JDD

Published: August 05, 2026

Psoriasiform Dermatitis Following JAK Inhibitor Therapy for Hidradenitis Suppurativa and Crohn's Disease.

Psoriasiform Dermatitis Following JAK Inhibitor Therapy for Hidradenitis Suppurativa and Crohn's Disease.

Journal: Cureus

Published: August 05, 2026

Anti-TNF, Pan-JAK, and JAK1-Selective Inhibition Differentially Alter Mechanisms of Flow-Mediated Dilation in Human Microvessels.

Anti-TNF, Pan-JAK, and JAK1-Selective Inhibition Differentially Alter Mechanisms of Flow-Mediated Dilation in Human Microvessels.

Journal: American journal of physiology. Heart and circulatory physiology

Published: August 04, 2026

PANCCO Clinical Practice Guideline Update for the treatment of ulcerative colitis in adults

PANCCO Clinical Practice Guideline Update for the treatment of ulcerative colitis in adults

Journal: Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru

Published: July 25, 2026

Anti-inflammatory efficacy of diosgenin in an oxazolone-induced model of ulcerative colitis in mice via suppression of Th2 pathways and pSTAT3 expression: A prospective study.

Anti-inflammatory efficacy of diosgenin in an oxazolone-induced model of ulcerative colitis in mice via suppression of Th2 pathways and pSTAT3 expression: A prospective study.

Journal: Science progress

Published: July 21, 2026

Vulvovaginal Lichen Planus Treatment Outcomes: A Systematic Review of Novel and Established Therapies.

Vulvovaginal Lichen Planus Treatment Outcomes: A Systematic Review of Novel and Established Therapies.

Journal: Journal of cutaneous medicine and surgery

Published: July 20, 2026

Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trial.

Study of TOfacitinib for the treatment of chronic PouchITis (STOPit): a multi-centre open label induction with randomised, double blind, placebo-controlled maintenance trial.

Journal: BMJ open

Published: July 17, 2026

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis.

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: July 13, 2026

Showing 1-12 of 4,341

Last Updated: 09/26/2026